Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CWUU | ISIN: US00534A1025 | Ticker-Symbol:
NASDAQ
06.06.25 | 21:59
0,985 US-Dollar
+6,46 % +0,060
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
INVIVYD INC Chart 1 Jahr
5-Tage-Chart
INVIVYD INC 5-Tage-Chart

Aktuelle News zur INVIVYD Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
29.05.H.C. Wainwright senkt Kursziel für Invivyd-Aktie auf 5 US-Dollar, behält Kaufempfehlung bei-
29.05.Invivyd stock target cut to $5 by H.C. Wainwright, retains Buy rating1
INVIVYD Aktie jetzt für 0€ handeln
27.05.Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, ...168CANOPY assessed pemivibart safety and tolerability, antiviral immunobridging, and exploratory efficacy against COVID-19, and is the only clinical trial of an authorized or approved COVID-19 monoclonal...
► Artikel lesen
23.05.Invivyd's antibody gains spot in cancer guidelines for COVID-19 PrEP2
23.05.Invivyd Announces Inclusion of PEMGARDA (pemivibart) in National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas128WALTHAM, Mass., May 23, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), today announced that PEMGARDA® (pemivibart), its investigational monoclonal antibody, has been added to the National...
► Artikel lesen
21.05.Invivyd Says Pemivibart Confers 84% Reduction In COVID-19 Risk, To Engage FDA With Expedited Pathway1
21.05.Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19137FDA acknowledges that the benefit of repeat doses of COVID-19 vaccine boosters for Americans is uncertain; the updated regulatory framework for COVID-19 vaccines articulated by the Agency generally...
► Artikel lesen
20.05.Invivyd, Inc. - 8-K, Current Report4
15.05.Invivyd GAAP EPS of -$0.14 misses by $0.11, revenue of $11.3M misses by $23.15M3
15.05.Invivyd Q1 2025 slides: Revenue grows amid regulatory hurdles and cash concerns3
15.05.Invivyd, Inc. - 10-Q, Quarterly Report1
15.05.Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights111PEMGARDA (pemivibart) net product revenue of $11.3 million reported for Q1 2025, influenced by planned transition (Jan/Feb) from a contracted to an internalized sales forcePEMGARDA revenue re-acceleration...
► Artikel lesen
14.05.What to Expect from Invivyd's Earnings1
14.05.Invivyd fordert modernisierte FDA-Impfstoffrichtlinien2
14.05.Invivyd calls for modernized FDA vaccine guidelines1
14.05.Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy59WALTHAM, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced it has submitted a Citizen Petition with the U.S. Food and Drug Administration (FDA) calling on the Agency...
► Artikel lesen
12.05.Invivyd beginnt mit der Entwicklung eines monoklonalen Antikörpers gegen Masern5
12.05.Invivyd begins discovery of measles monoclonal antibody2
12.05.Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles450Multiple HCPs have requested from Invivyd a monoclonal antibody (mAb) for treatment of active measles infection and post-exposure prophylaxis to reduce the consequence of outbreaks. Such a medicine...
► Artikel lesen
12.05.Invivyd, Inc. - 8-K, Current Report1
Weiter >>
70 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1